2026-07-05 · medications, orlistat, xenical, alli, obesity medicine, OTC, lipase inhibitor, prescription · 21 min read

How much weight loss should I actually expect on orlistat?

In the four-year XENDOS trial (Torgerson 2004, Diabetes Care) of 3,305 adults with BMI ≥ 30, orlistat 120 mg three times daily produced a mean 5.8 kg loss versus 3.0 kg on placebo at four years — roughly 2.8 kg placebo-adjusted, sustained. The one-year Davidson 1999 US trial (JAMA) reported 8.8% on 120 mg versus 5.8% on placebo. Meta-analysis of 16 randomized trials (Anderson 2010, Annals of Pharmacotherapy) pooled to roughly 2.9 kg placebo-adjusted at one year and a 2.5-fold higher chance of losing at least 5% of baseline weight. Honest positioning: orlistat delivers roughly a quarter of the effect of semaglutide 2.4 mg (~15% at 68 weeks in Wilding 2021 STEP-1) and roughly a fifth of tirzepatide 15 mg (~21% at 72 weeks in Jastreboff 2022 SURMOUNT-1). Real-world persistence is the ceiling on that number — Kim 2016 (Obesity Research and Clinical Practice) reported 26-week adherence around 30–40%, and Wharton 2020 (Obesity Science and Practice) reported 12-month adherence of 12–18% in Canadian real-world use, driven mostly by GI intolerance and the three-times-daily pill burden.

What is the difference between Alli 60 mg over the counter and Xenical 120 mg by prescription?

Chemically the same drug at two doses. Xenical is 120 mg orlistat by prescription, taken three times daily with fat-containing meals. Alli is 60 mg over the counter — half the dose — approved in 2007 as the first and still only OTC weight-loss drug in the United States. The pivotal Broom 2002 trial (International Journal of Obesity) showed the 60 mg dose delivered roughly 85% of the 120 mg effect (about 4.8 kg vs 3.1 kg placebo at one year), which is why the FDA accepted the OTC application — the 50% dose gave most of the benefit with a modestly better GI-side-effect profile. Alli is a legitimate medication, not a supplement — it has the same active ingredient, the same mechanism, the same drug-drug interactions, and the same 2010 hepatotoxicity warning as Xenical. If tolerated Alli well and 60 mg is not delivering enough, escalation to Xenical 120 mg with prescriber oversight is reasonable.

How does orlistat block fat absorption without being absorbed itself?

Orlistat is a lipstatin analogue that forms a covalent, irreversible bond with the active serine site of gastric and pancreatic lipase enzymes in the gut lumen (Zhi 1996, Clinical Pharmacology and Therapeutics). Without functioning lipase, dietary triglycerides cannot be broken down into free fatty acids and monoglycerides for absorption, and roughly 30% of ingested fat passes through the GI tract unabsorbed and is eliminated in stool. Because orlistat acts locally in the gut lumen and is only about 1% systemically absorbed, it has essentially no CNS side-effect profile, minimal drug-drug interactions on the pharmacokinetic side (the important ones — cyclosporine, levothyroxine, warfarin — are absorption-timing issues, not CYP interactions), and a safety profile in adolescents and older adults that no other weight-loss drug can match. The trade-off is that the effect is proportional to dietary fat intake — a low-fat meal produces little drug effect and little side effect; a very-high-fat meal produces the most weight loss and the worst oily-stool and flatus-with-oil events.

What are the oily-stool and spotting side effects, and how do I reduce them?

Oily spotting, oily discharge, fatty or oily stool, increased defecation, urgent bowel movements, flatus with discharge, and fecal incontinence are the signature GI events on orlistat (Filippatos 2008, Drug Safety). They are the drug working — the unabsorbed 30% of fat has to exit the GI tract somehow, and it does. The single most effective mitigation is a moderate-fat diet: keep fat intake below roughly 30% of total calories and no more than about 15 grams of fat per meal. Eating a high-fat meal (a burger and fries, a slice of pizza with pepperoni) while on orlistat almost guarantees oily spotting within 24 to 48 hours. Practical mitigations: take orlistat with meals containing fat (skip the dose if a meal has essentially no fat), keep a change of underwear available during the first month, avoid tight clothing, and expect the effect to plateau after several weeks as most patients naturally recalibrate their eating toward lower-fat foods. Symptoms are usually the reason to eat differently, not the reason to stop the drug.

Do I need to take a multivitamin with orlistat?

Yes. Because orlistat blocks fat absorption, it also blocks a modest fraction of fat-soluble vitamin (A, D, E, K) and beta-carotene absorption (Poirier 2011). The clinical effect is small in most well-nourished adults over a year of therapy but is real in longer-term use, in adolescents whose diets are less balanced, and in adults with baseline low vitamin D or vitamin K levels. The prescribing information and clinical practice both recommend a standard once-daily multivitamin that contains fat-soluble vitamins, taken at least two hours away from any orlistat dose (typically at bedtime if orlistat is taken with meals). Warfarin patients on orlistat need INR monitoring for possible vitamin K malabsorption effects. Adolescents 12 to 17 on orlistat should have their multivitamin schedule documented in the prescription plan (Chanoine 2005 pediatric protocol).

How does orlistat prevent type 2 diabetes?

The four-year XENDOS trial (Torgerson 2004, Diabetes Care) is the reason orlistat still shows up in the diabetes-prevention conversation. Of 3,305 adults with BMI ≥ 30 randomized to orlistat 120 mg three times daily plus lifestyle intervention or lifestyle intervention alone, cumulative incidence of type 2 diabetes at four years was 9.0% in the placebo group versus 6.2% in the orlistat group — a 37.3% relative reduction. The absolute-risk benefit was concentrated in the prediabetes subgroup, where roughly one in four progressions to T2D was averted. Mechanistically, most of the effect is explained by the modest but sustained weight loss (about 2.8 kg placebo-adjusted); a smaller fraction may reflect direct effects on postprandial lipid load and hepatic fat. Orlistat is a legitimate option for prediabetes patients who cannot tolerate metformin (GI intolerance, chronic kidney disease with reduced eGFR, or a history of lactic-acidosis concern) — see metformin and weight for the primary comparison.

Is orlistat safe during pregnancy, breastfeeding, or when planning pregnancy?

Orlistat is categorically not recommended during pregnancy — fat-soluble vitamin (A, D, E, K) malabsorption is theoretically harmful in early fetal development, and the manufacturer, FDA labelling, and every obstetric guideline align on this. It is also not recommended during breastfeeding due to a lack of safety data. In pregnancy-planning windows, however, orlistat has a distinct positioning advantage: because it is not systemically absorbed to any meaningful degree and has no CNS activity, it is more compatible with a plan-to-conceive timeframe than Qsymia (a REMS-registered teratogen with a strict pregnancy-testing requirement), Contrave (bupropion is a mixed pregnancy signal and naltrexone crosses the placenta), or the GLP-1s (limited data and current guidance recommends discontinuing at least two months before conception). Orlistat can be used up to the point of conception and immediately discontinued at the first positive pregnancy test. Prescribers still often stop orlistat several weeks before an intended conception window to allow fat-soluble vitamin stores to recover — this is a practical planning point, not a pharmacologic requirement.

How does orlistat compare to Wegovy, Zepbound, Contrave, Qsymia, and Saxenda?

Orlistat delivers roughly 3–4 kg placebo-adjusted weight loss at one year — roughly a quarter of Wegovy's effect (~15% at 68 weeks in Wilding 2021 STEP-1), roughly a fifth of Zepbound's (~21% at 72 weeks in Jastreboff 2022 SURMOUNT-1), roughly two-thirds of Contrave's (~5% at 56 weeks in Greenway 2010 COR-I), roughly one-third of Qsymia's top dose (~10% at 56 weeks in Allison 2012 EQUIP), and roughly half of Saxenda's (~6–8% at 56 weeks in Pi-Sunyer 2015 SCALE). Where orlistat earns its place is not effect size but the constraints the other drugs cannot meet: it is the only OTC option, the only drug with no CNS side-effect profile, the only drug you can start compatibly with a pregnancy-planning window, an FDA-approved adolescent option (12+) since 2003, and the only weight-loss drug with a four-year prevention-of-T2D outcome trial (XENDOS). See prescription weight loss medications for the broader comparison landscape.

Orlistat (Xenical, Alli) for Weight Loss: How the Only FDA-Approved Lipase Inhibitor Works and When It Still Makes Sense

Quick stats

• Placebo-adjusted weight loss at four years (Torgerson 2004 XENDOS, Diabetes Care): mean 5.8 kg on orlistat 120 mg three times daily vs 3.0 kg on placebo — roughly 2.8 kg placebo-adjusted, sustained, the only long-term trial of any weight-loss drug reaching four years.
• XENDOS type 2 diabetes prevention (Torgerson 2004): 37.3% relative reduction in progression to T2D over four years in the prediabetes subgroup.
• Alli 60 mg OTC dose (Broom 2002, International Journal of Obesity): mean 4.8 kg vs 3.1 kg placebo at one year — roughly 85% of the Xenical effect at 50% of the dose, the basis for the 2007 FDA over-the-counter approval.
• Mechanism (Zhi 1996, Clinical Pharmacology and Therapeutics): irreversible inhibition of gastric and pancreatic lipases in the gut lumen; approximately 30% of dietary fat blocked from absorption; only about 1% systemic absorption.
• GI events are the signature side effect (Filippatos 2008, Drug Safety): oily spotting, fatty stool, urgent defecation, flatus with discharge — the drug working; keep meal fat below roughly 15 g per meal to reduce severity.
• Emergency red flags: dark urine + severe abdominal pain — call 911 (rare hepatotoxicity signal per FDA 2010 advisory); severe flank pain with oily diarrhoea and dehydration — urgent evaluation (oxalate nephropathy signal per FDA 2011); suspected overdose or accidental ingestion in children — Poison Control 1-800-222-1222.

The honest picture, in one paragraph

Orlistat produces roughly 3–4 kg placebo-adjusted weight loss at one year on the 120 mg three-times-daily dose (Anderson 2010 meta-analysis; Padwal 2006 Cochrane) — real, reproducible, and durable in adherent patients through four years (Torgerson 2004 XENDOS). Head-to-head against modern GLP-1s it delivers roughly a quarter of Wegovy’s effect (~15% at 68 weeks in Wilding 2021 STEP-1) and a fifth of Zepbound’s (~21% at 72 weeks in Jastreboff 2022 SURMOUNT-1). It earns its place — despite prescriptions declining ~90% since 2013 as GLP-1 use expanded (CDC 2023) — because it is the only OTC option (Alli 60 mg since 2007), the only weight-loss drug with no CNS profile, the only option compatible with pregnancy-planning windows where Qsymia (teratogen), Contrave (CNS), and GLP-1s (limited data) are not, an FDA-approved adolescent option since 2003 (Chanoine 2005), and a legitimate T2D-prevention drug in prediabetes patients who cannot tolerate metformin (XENDOS 37.3% relative reduction). Three-times-daily pill burden and GI side effects remain the two biggest reasons patients discontinue — real-world 12-month persistence is 12–18% (Wharton 2020).

How orlistat fits into the FDA-approved obesity drug lineup

Orlistat is the oldest FDA-approved obesity drug still on the market. This primer table sets the field in one place.

Why orlistat works (and does not work as well as newer drugs) for weight

Four mechanistic threads explain both the modest effect size and the safety profile that lets orlistat still earn a place in the treatment landscape.

1. Gastric and pancreatic lipase inhibition (Zhi 1996)

Orlistat is a lipstatin analogue that forms a covalent, irreversible bond with the active serine site of gastric and pancreatic lipase enzymes in the gut lumen. Without functioning lipase, dietary triglycerides cannot be hydrolyzed to free fatty acids and monoglycerides for absorption. Approximately 30% of ingested fat passes through the GI tract unabsorbed and is excreted in stool (Zhi 1996). Every downstream effect — weight loss, GI side effects, fat-soluble vitamin malabsorption, LDL reduction (Rossner 2000) — flows from this single mechanism.

2. Only about 1% systemic absorption

Because orlistat acts locally in the gut lumen and only around 1% of an oral dose is systemically absorbed, it has essentially no CNS side-effect profile, no cardiovascular stimulant effect, and one of the safest drug-drug interaction profiles of any obesity drug — the important interactions (cyclosporine, levothyroxine, warfarin) are absorption-timing issues, not CYP-mediated. This is the reason orlistat is FDA-approved for adolescents 12+, is compatible with pregnancy-planning windows, and can be sold OTC. The trade-off is that the drug’s effect is confined to the lumen, and that ceiling is real.

3. The effect is proportional to dietary fat intake

Orlistat is not an appetite suppressant. It has no independent effect on hunger, satiety, gastric emptying, reward circuits, or thermogenesis. Its clinical effect is a direct function of how much fat is eaten and how much of that fat the drug blocks. Patients eating under ~30% of calories from fat see minimal drug effect and minimal side effects; patients eating over ~40% fat see more weight loss and dramatically worse GI events. The drug is the enforcement mechanism for a moderate-fat diet, not a licence to eat more fat.

4. What orlistat is not

Orlistat is not an appetite suppressant, not a CNS drug, not a GLP-1, and not a substitute for a calorie deficit — the caloric equivalent of the ~30% of dietary fat it blocks averages roughly 150–200 kcal/day, exactly the mechanistic order of magnitude of the 3–4 kg placebo-adjusted one-year weight loss. It is not appropriate for chronic malabsorption disorders (celiac, active IBD, chronic pancreatitis), cholestasis, or history of oxalate nephropathy, and not a replacement for a GLP-1 in an adult who can access one — the effect-size gap is too large to argue otherwise.

Dose and dietary counselling

Orlistat comes in two strengths: Alli 60 mg OTC and Xenical 120 mg by prescription. Both are taken three times daily during or up to one hour after a fat-containing meal. If a meal contains essentially no fat (a plain green salad, a fat-free snack), skip the dose — the drug has nothing to inhibit and the pill burden delivers no benefit.

Practical rule: The GI side effects are the drug enforcing the dietary contract. Patients who reduce meal fat below roughly 15 g per meal experience the fewest events, and most patients naturally recalibrate their eating within 4 to 8 weeks. Symptoms are usually a reason to eat differently, not a reason to stop the drug.

Time-course and outcomes

The trajectory across the pivotal one-, two-, and four-year trials is unusually well characterized because orlistat is the oldest FDA-approved obesity drug and has been studied the longest.

5-step orlistat protocol

This is the pathway that matches the FDA 1999/2007 labelling, the AACE 2016 Obesity Clinical Practice Guideline, the ADA 2024 Standards of Care Section 8, and the NICE 2014 CG189 obesity guideline (which places orlistat as first-line pharmacotherapy in the UK context — a contrast with the US GLP-1-first landscape).

Step 1: Confirm the indication

Xenical 120 mg is indicated for adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, or T2D). Use the BMI calculator to check. Alli 60 mg is available OTC for adults with BMI ≥ 25 without formal comorbidity screening. Adolescents 12 to 17 have been eligible for Xenical 120 mg since the 2003 FDA pediatric extension (Chanoine 2005) — see adolescent and teen weight management.

Step 2: Screen for exclusions

Absolute contraindications and important precautions before starting orlistat:

• Chronic malabsorption syndromes — celiac disease, active inflammatory bowel disease, chronic pancreatitis, short-bowel syndrome.
• Cholestasis — impaired biliary excretion of unabsorbed fat.
• Pregnancy or planned conception within the next several weeks — see the pregnancy-planning FAQ above; discontinue on any positive pregnancy test.
• Breastfeeding — no adequate data.
• Cyclosporine co-administration — orlistat reduces cyclosporine absorption; space by at least 3 hours or avoid.
• History of oxalate nephropathy or nephrolithiasis — the FDA 2011 renal-injury signal.
• Post-bariatric anatomy — already-shortened absorptive surface; consider only case-by-case with surgeon input.
• Chronic warfarin therapy — vitamin K malabsorption can alter INR; possible but requires monitoring.

Step 3: Baseline

Baseline weight, waist circumference, and a rough dietary-fat estimate. Recommend a once-daily multivitamin containing fat-soluble vitamins A, D, E, K taken at least two hours away from any orlistat dose (typically at bedtime). Warfarin patients need a baseline INR and closer monitoring in the first several weeks.

Step 4: Counsel and start

Meal-fat ceiling ~15 g of fat per meal (about 30% of calories from fat across the day). Frame the drug as the enforcement mechanism for a moderate-fat diet, not a licence to eat more fat. Expect oily spotting, oily stool, urgent defecation, and flatus with oil in the first month. Skip any dose taken with a meal containing essentially no fat.

Step 5: Reassess at 12 weeks

On Xenical 120 mg, less than 5% baseline weight loss combined with poor tolerance is the discontinuation trigger — escalate to a newer agent (a GLP-1, Qsymia, or Contrave) or reset expectations. On Alli 60 mg OTC, less than 3% at 12 weeks with poor tolerance is the point to consider Rx escalation or a mechanistic switch. Continue quarterly weight, BP, and where relevant A1c or LDL monitoring.

What treatments actually do — comparison

Special situations

The only OTC weight-loss drug — Alli

Alli 60 mg orlistat is the only over-the-counter weight-loss drug approved by the FDA and remains the only OTC option nearly two decades after its 2007 approval. Alli is a legitimate medication, not a supplement — same active ingredient as prescription Xenical, same mechanism, same drug-drug interactions, same 2010 FDA hepatotoxicity advisory. The 2007 approval was grounded in Broom 2002 showing the 60 mg dose delivered ~85% of the 120 mg Xenical effect with modestly better GI tolerance. Alli is a reasonable start for adults with BMI ≥ 25 who want a pharmacologic assist without a prescription visit and will accept the moderate-fat contract. Escalate to Xenical 120 mg if 60 mg is well tolerated but under-delivering. See weight loss supplements overview for how Alli differs from OTC supplements, which are not FDA-approved and lack equivalent evidence.

Adolescents 12 and older (Chanoine 2005)

Orlistat is the oldest FDA-approved obesity pharmacotherapy option for adolescents. The 2003 FDA extension of Xenical 120 mg to ages 12 to 17 was grounded in the pivotal Chanoine 2005 trial (JAMA) of 539 adolescents with obesity, showing BMI reduction of −0.55 kg/m² on orlistat versus +0.31 on placebo at one year. The AAP 2023 CPG places orlistat as a legitimate adolescent option alongside liraglutide, semaglutide, and (as of 2022) phentermine-topiramate. What distinguishes it is the benign systemic-safety profile — no CNS activity, no cardiovascular stimulant effect, no boxed warning — unmatched by any other adolescent-eligible weight-loss drug. Multivitamin supplementation matters more in adolescents whose baseline diets may already be marginal in fat-soluble vitamins. See adolescent and teen weight management.

Prediabetes and type 2 diabetes prevention (XENDOS)

XENDOS (Torgerson 2004, Diabetes Care) is the reason orlistat still shows up in the diabetes-prevention conversation. Over four years in 3,305 adults with BMI ≥ 30, orlistat 120 mg three times daily produced a 37.3% relative reduction in progression to T2D — concentrated in the prediabetes subgroup, where roughly one in four progressions was averted. This is a legitimate alternative to metformin for prediabetes patients who cannot tolerate metformin’s GI profile, who have CKD with reduced eGFR, or who have a documented lactic-acidosis concern. Orlistat and metformin can also be combined (see next section). See prediabetes and weight loss and metformin and weight for the surrounding context.

Pregnancy planning windows

Orlistat is categorically contraindicated during pregnancy — fat-soluble vitamin depletion is a theoretical harm at a life stage where it cannot be justified. But orlistat’s ~1% systemic absorption and absence of CNS activity make it distinctly compatible with pre-conception planning windows in ways other weight-loss drugs are not. Qsymia is a REMS-registered first-trimester teratogen. Contrave includes bupropion (a mixed pregnancy signal) and naltrexone (crosses the placenta). GLP-1s have limited pregnancy data and current guidance recommends discontinuation at least two months before conception. Orlistat can be continued up to conception and discontinued at the first positive pregnancy test. Many prescribers still stop it several weeks before intended conception to allow fat-soluble vitamin stores to recover — a practical planning point, not a pharmacologic requirement. See weight loss women over 40 for adjacent life-stage considerations.

T2D with orlistat plus metformin (Miles 2002)

For adults with T2D on metformin who need additional weight and glycemic effect but cannot access or tolerate a GLP-1, adding orlistat is a legitimate pharmacologic combination. Miles 2002 (Diabetes Care) in 503 metformin-treated T2D adults showed orlistat added to metformin produced an additional 2.3 kg weight loss and 0.36% A1c reduction over metformin plus placebo at one year. Hollander 1998 in sulfonylurea-treated T2D showed a similar pattern (−6.2% vs −4.3% weight, A1c −0.6% vs +0.2%). The additive effect is modest but real, and the fat-malabsorption mechanism is independent of incretin, biguanide, and SGLT2 pathways — see diabetes and weight loss.

Cyclosporine, levothyroxine, warfarin timing

Orlistat’s clinically important drug interactions are absorption-timing issues rather than CYP-mediated pharmacokinetic interactions. Cyclosporine: orlistat reduces cyclosporine absorption; space doses by at least 3 to 4 hours or avoid orlistat entirely in transplant patients. Levothyroxine: orlistat can reduce T4 absorption; space doses by at least 4 hours, monitor TSH within 6 to 8 weeks of starting, and be prepared to adjust the T4 dose. Warfarin: orlistat’s effect on fat-soluble vitamin K absorption can alter INR unpredictably; monitor INR more frequently in the first 4 to 6 weeks of therapy. Amiodarone: possible reduced absorption; monitor. Because orlistat has essentially no CYP-mediated interactions and no CNS profile, the interaction list is shorter and more predictable than for the other weight-loss drugs.

Post-bariatric patients

Orlistat is generally not recommended after bariatric surgery. Sleeve gastrectomy, Roux-en-Y, and other bariatric anatomies have already shortened the absorptive surface for fat, and adding a lipase inhibitor produces disproportionately severe GI events (steatorrhea, urgency, electrolyte and fat-soluble vitamin depletion) without meaningful additional weight-loss benefit. If bariatric weight regain is the clinical issue, the higher-yield pharmacologic options are the GLP-1s and Qsymia. Consider orlistat only case-by-case with surgeon input.

Red flags — when to call for help

Some symptoms on orlistat are not routine and warrant same-day evaluation or emergency care.

• Dark urine + severe abdominal pain (right upper quadrant), jaundice, or unexplained fatigue — potential hepatotoxicity signal per FDA 2010 Xenical / Alli hepatotoxicity advisory (roughly 13 cases of severe liver injury reported across an estimated 30 million users). Call 911 if accompanied by fever or altered mental status; otherwise, urgent same-day evaluation and discontinue orlistat.
• Severe flank pain with unremitting oily diarrhoea and signs of dehydration — potential oxalate-nephropathy signal per FDA 2011 renal-injury advisory. Urgent same-day evaluation; ensure aggressive rehydration.
• INR spike or unexpected bleeding on warfarin — vitamin K malabsorption effect; contact the anticoagulation clinic; do not stop warfarin without direction.
• New hypothyroidism symptoms (fatigue, cold intolerance, constipation) on levothyroxine — likely a dose-spacing issue with orlistat; check TSH; adjust dose or spacing.
• New IBD flare, new severe pancreatitis, or new severe malabsorption symptoms — stop orlistat and evaluate for the underlying condition.
• Suspected overdose or accidental pediatric ingestion — call Poison Control at 1-800-222-1222 (US) immediately.

How this connects to the rest of the site

For the broader medication landscape, see prescription weight loss medications and weight loss drug safety. For direct pharmacotherapy comparisons, see saxenda for weight loss, wegovy for weight loss, zepbound for weight loss, contrave for weight loss, qsymia for weight loss, and phentermine for weight loss. For the T2D-prevention and metformin discussion, see metformin and weight and prediabetes and weight loss. For adolescent options, see adolescent and teen weight management. For meal-fat planning, see 1200 calorie meal plan, 1500 calorie meal plan, and 1800 calorie meal plan. For adjacent life-stage considerations, see weight loss women over 40 and weight loss supplements overview. For baseline vital-signs monitoring, see blood pressure and weight loss.

Bottom line

Orlistat is not the strongest weight-loss drug on the market — a GLP-1 will beat it on the scale by roughly a factor of four, and tirzepatide by roughly a factor of five. What orlistat is, is the only OTC option, the only drug with no CNS profile, an FDA-approved adolescent option since 2003, the only drug compatible with pregnancy-planning windows in ways teratogenic or CNS-active drugs are not, and the only weight-loss drug with a four-year outcome trial (XENDOS) — a 37% relative reduction in progression to type 2 diabetes. It comes with a real GI side-effect profile that is the drug enforcing a moderate-fat dietary contract, a rare but real 2010 hepatotoxicity signal, a rare but real 2011 oxalate-nephropathy signal, and a real-world 12-month persistence of 12–18% that ceilings what the drug actually delivers. The 15 g fat-per-meal ceiling, a fat-soluble-vitamin multivitamin taken two hours away from any dose, and the 12-week reassessment are the safety architecture that keeps orlistat a reasonable choice. If those constraints fit you and your prescriber — or if you meet the OTC eligibility for Alli 60 mg — the 3–4 kg placebo-adjusted first-year weight loss, layered on the calorie-deficit and behavioural work everything else depends on, is a real, useful result.

Orlistat FAQ

How much weight loss should I expect? Roughly 3–4 kg placebo-adjusted at one year on Xenical 120 mg three times daily — about a quarter of Wegovy and a fifth of Zepbound.

Alli vs Xenical? Alli is 60 mg OTC; Xenical is 120 mg by prescription. Same drug. The 60 mg dose delivers ~85% of the 120 mg effect (Broom 2002).

How does it work? Irreversible inhibition of gut lipase blocks about 30% of dietary fat absorption (Zhi 1996). Only ~1% is systemically absorbed.

Can adolescents use it? Yes — FDA-approved for ages 12+ since 2003 (Chanoine 2005), placed alongside GLP-1s in the AAP 2023 CPG.

What is the T2D-prevention effect? In XENDOS (Torgerson 2004), orlistat produced a 37.3% relative reduction in progression to T2D over four years in the prediabetes subgroup.

How do I reduce the oily-stool side effects? Keep meal fat below roughly 15 g per meal; skip doses at very-low-fat meals; the effect usually plateaus after several weeks as diet recalibrates.

Do I need a multivitamin? Yes — a once-daily multivitamin with fat-soluble vitamins A, D, E, K, taken at least two hours away from any orlistat dose (typically at bedtime).

Is it safe in pregnancy planning? More compatible than Qsymia, Contrave, or GLP-1s. Discontinue at the first positive pregnancy test.